A combination of glecaprevir and pibrentasvir (Mavyret), has been approved for hepatitis C treatment, for any genotype, with a treatment duration of only eight weeks -- four weeks less than most other current regimens.
There are several emerging treatments for hepatitis C virus. Here is a brief guide to some drugs and the classes to which they belong.
"Last month, the Cochrane Review published a controversial paper on HCV therapy that left many ID doctors and hepatologists perplexed," writes Paul Sax, M.D.
Researchers in San Diego, Calif., said that having both "mental health and substance diagnoses" was not a barrier to successful HCV treatment.
For homeless people who may be reluctant to engage with hospital-based services, researchers in Brighton, England established a liver monitoring and care service located in the community that focused on people 40 years and older.
Researchers conducted a study to assess the impact of direct-acting antivirals on issues such as mood and factors affected by mood, such as physical activity and fatigue.
Researchers found that people who were cured of hepatitis C virus underwent "significant improvement" in blood sugar levels and in many cases participants' doctors were able to reduce the dose of medicines used to help control blood sugar.
"Vosevi provides a treatment option for some patients who were not successfully treated with other HCV drugs in the past."
Individuals who inject cocaine and methamphetamine and men who have sex with men (MSM) with high sexual risk had the greatest chance of hepatitis C (HCV) reinfection after sustained virologic response.
What Will It Take to Eliminate HCV in the U.S.? The WHO Global Hepatitis Report Puts It Into the Global Context
According to the WHO's first-ever Global Hepatitis Report, approximately 1.75 million people were infected with hepatitis C in 2015, bringing the total number to 71 million. What can the US and other countries do to bring these numbers down?